Expression of cysteine protease cathepsin L is increased in endometrial cancer and correlates with expression of growth regulatory genes

Cancer Investigation

Volumn 30, Issue 5, 2012, Pages 398-403

  Skrzypczak, MacIej ^a,b   Springwald, Anette ^a   Lattrich, Claus ^a   Häring, Julia ^a   Schüler, Susanne ^a   Ortmann, Olaf ^a   Treeck, Oliver ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cathepsin L; Endometrial cancer; Endometrium

Indexed keywords

CATHEPSIN L; CYCLIN B1; CYSTEINE PROTEINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MYBL2 PROTEIN; PROTEIN; PROTEIN P21; STROMELYSIN 3; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CATHEPSINS; CYCLIN B1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYSTEINE ENDOPEPTIDASES; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 11; MIDDLE AGED; RNA, MESSENGER;

EID: 84861016229     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.672608     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y,Xu J,Murray T,ThunMJ.Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Eichhorst ST, Krammer PH. Derangement of apoptosis in cancer. Lancet 2001;358:345-346. (Pubitemid 32739089)
3. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003;3:659-671. (Pubitemid 37236408)
4. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007;28:297-321. (Pubitemid 46984829)
5. Lah TT, Durán Alonso MB, Van Noorden CJ. Antiprotease therapy in cancer: hot or not? Expert Opin BiolTher 2006;6:257-279. (Pubitemid 43344745)
6. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5:785-799. (Pubitemid 44323703)
7. Lankelma JM, VoorendDM, BarwariT,Koetsveld J, Van der Spek AH, De Porto AP, Van Rooijen G, Van Noorden CJ. Cathepsin L, target in cancer treatment? Life Sci 2010;86:225-233.
8. Gocheva V, Joyce JA. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007;1:60-64. (Pubitemid 46173882)
9. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A 1962;48:1014-1022.
10. López-Otín C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-808. (Pubitemid 47463671)
11. Rio, MC. From a unique cell to metastasis is a long way to go: clues to stromelysin-3 participation. Biochimie 2005;87:299-306. (Pubitemid 40387608)
12. Engel G, Heselmeyer K, Auer G, Bäckdahl M, Eriksson E, Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int J Cancer 1994;58:830-835. (Pubitemid 24306372)
13. Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-775. (Pubitemid 44450465)
14. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem 2004;385:1017-1027. (Pubitemid 39600309)
15. Joyce JA,HanahanD.Multiple roles for cysteine cathepsins incancer. Cell Cycle 2004;3:1516-1619.
16. Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. Biochem Soc Symp 2003;70:179-199.
17. Jokimaa V, Oksjoki S, Kujari H, Vuorio E, Anttila L. Expression patterns of cathepsins B, H, K, L and S in the human endometrium. Mol Hum Reprod 2001;7:73-78. (Pubitemid 32101767)
18. Goulet B, Sansregret L, Leduy L, Bogyo M,Weber E, Chauhan SS, Nepveu A. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol Cancer Res 2007;5:899-907. (Pubitemid 47416667)
19. Lacey JV Jr, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68:6014-6020.
20. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, Ellenson LH, Dey SK. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer inmice. Cancer Res 2008;68:5619-5627.
21. HetzelDJ,Wilson TO, Keeney GL, Roche PC, Cha SS, Podratz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-185. (Pubitemid 23001325)
22. Wang D, Konishi I, Koshiyama M,Mandai M, Nanbu Y, Ishikawa Y, Mori T, Fujii S. Expression of c-erbB-2 protein and epidermal growth receptor in endometrial carcinomas. Correlation with clinicopathologic and sex steroid receptor status. Cancer 1993;72:2628-2637. (Pubitemid 23320224)
23. Clarke, BA, Gilks, CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol 2010;63:410-415.
24. LivakKJ, SchmittgenTD. Analysis of relative gene expressiondata using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
25. Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ, Lah TT. Selective suppression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer GeneTher 2003;10:141-151. (Pubitemid 36228262)
26. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006;20:543-556. (Pubitemid 43345321)
27. Niedergethmann M,Wostbrock B, Sturm JW, Willeke F, Post S, Hildenbrand R. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004;29(3): 204-211. (Pubitemid 39304977)
28. Nasu K, Kai K, Fujisawa K, Takai N, Nishida Y, Miyakawa I. Expression of cathepsin L in normal endometrium and endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2001;99(1):102-105. (Pubitemid 32936937)
29. Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA. Stromelysin-3 is overexpressed by stromal elements in retinoic acid in pulmonary fibroblasts primarynon-small cell lung cancers and regulatedby retinoic acid in pulmonary fibroblasts. Cancer Res 1995;55:4120-4126.
30. Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, ChenardMP, RioMC, Chambon P. A novelmetalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704. (Pubitemid 120015135)
31. Callegari EA, Ferguson-Gottschall S, Gibori G. PGF2alpha induced differential expression of genes involved in turnover of extracellular matrix in rat decidual cells. Reprod Biol Endocrinol 2005;11:3.
32. Song G, Spencer TE, Bazer FW. Cathepsins in the ovine uterus: regulation by pregnancy, progesterone, and interferon tau. Endocrinology 2005;146(11):4825-4833. (Pubitemid 41446620)
33. Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T, Konishi I. Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor-suppressor gene products, Ki-67, and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as a poor prognostic indicator. Hum Pathol 2003;34:471-478. (Pubitemid 36666813)
34. Horree N, van Diest PJ, van der Groep P, Sie-Go DM, Heintz AP. Progressive derailment of cell cycle regulators in endometrial carcinogenesis. J Clin Pathol 2008;61:36-42. (Pubitemid 351158223)
35. Oreskovic S, Babic D, Kalafatic D, Barisic D, Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 2004;93:34-40. (Pubitemid 38429546)
36. Chakravarty D, Gupta N, Goda JS, Srinivasan R, Patel FD, Dhaliwal L. Steroid receptors,HER2/neu andKi-67, in endometrioid type of endometrial carcinoma: correlation with conventional histomorphological features of prognosis. Acta Histochem 2010;112(4):355-365.
37. Uchikawa J, Shiozawa T, Shih HC, Miyamoto T, Feng YZ, KashimaH, OkaK,Konishi I. Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression. Cancer 2003;98:2207-2213. (Pubitemid 37392425)
38. Ikawa S, Sano T, Furumoto H, Aono T. Multidirectional differentiation of endometrial carcinoma with special reference to tumor aggressiveness evaluated by Ki-67 expression. Gynecol Oncol 1999;72:323-330. (Pubitemid 29118188)
39. MannefeldM, Klassen E, Gaubatz S. B-MYB is required for recovery from the DNAdamage-induced G2 checkpoint in p53 mutant cells. Cancer Res. 2009;69:4073-4080.
40. Shabani N, Mylonas I, Jeschke, Udo, Thaqi A, Kuhn C, Puchner T, Friese K. Expression of estrogen receptors α and β and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res 2007;27:2027-2034.
41. Curry, TE Jr, Osteen, KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003;24:428-465. (Pubitemid 37056240)
42. Gaide Chevronnay HP, Selvais C, Emonard H, Galant C, Marbaix E, Henriet P. Regulation of matrix metalloproteinases activity studied in human endometrium as a paradigm of cyclic tissue breakdown and regeneration. Biochim Biophys Acta 2012;1:46-56.
43. Goffin F, Munaut C, Frankenne F, Perrier D'Hauterive S, Béliard A, Fridman V, Nervo P, Colige A, Foidart JM. Expression pattern of metalloproteinases and tissue inhibitors of matrixmetalloproteinases in cycling human endometrium. Biol Reprod 2003;69:976-984. (Pubitemid 37064627)
44. Byers M, Kuiper GG, Gustafsson JA, Park-Sarge OK. Estrogen receptor-beta mRNA expression in rat ovary: down-regulation by gonadotropins. Mol Endocrinol 1997;11:172-182. (Pubitemid 27057430)
45. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson J-A. Estrogen receptor (ER) β, a modulator of ERα in the uterus. Proc Natl Acad Sci USA 2000;97:5936-5941.
46. Hall JM, McDonnell DP.The estrogen receptor β-isoform (ERβ) of the human estrogen receptormodulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-5578. (Pubitemid 30645344)